Adults 14 to 18, female only, with HIV or Risk Reduction Behavior. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Feasibility Assessed Using Change in Retention RatesPrimary· Baseline, 1 month and 4 months
Feasibility of this intervention is assessed by the percent of total questionnaires returned out of all distributed at each time point to assess retention rates. Rates \>80% indicate high retention.
Baseline
Group
Value
95% CI
InvestiDate Intervention
97.5
Non-Health Related Game
97.4
1 month
Group
Value
95% CI
InvestiDate Intervention
97.5
Non-Health Related Game
100
4 months
Group
Value
95% CI
InvestiDate Intervention
92.5
Non-Health Related Game
100
Acceptability Assessed Via Self-reported SurveyPrimary· 1 month
Acceptability of the intervention condition is assessed via self-reported survey at the post gameplay time point using the game experience and satisfaction questionnaire, which is a 10-item scale with 4-point Likert-type responses ranging from 1 (strongly disagree) to 4 (strongly agree). Total score range 10-40. Data were collected from participants in the experimental group only. Higher scores indicate stronger agreement with the statement.
I would play this game again
Group
Value
95% CI
InvestiDate Intervention
3.64
± 0.54
I was frustrated with this game
Group
Value
95% CI
InvestiDate Intervention
1.54
± 0.56
I would make decisions in real life like I made them in the game
Group
Value
95% CI
InvestiDate Intervention
3.44
± 0.75
I liked the way the game looked
Group
Value
95% CI
InvestiDate Intervention
3.51
± 0.68
I felt connected to the characters in the game
Group
Value
95% CI
InvestiDate Intervention
3.03
± 0.67
I felt responsible for the choices I made in the game
Group
Value
95% CI
InvestiDate Intervention
3.54
± 0.51
I liked talking with other players about what was happening in the game
Group
Value
95% CI
InvestiDate Intervention
3.51
± 0.56
I enjoyed playing the game agree
Group
Value
95% CI
InvestiDate Intervention
3.75
± 0.44
Acceptability Assessed by Favorite Investidate ActivitiesPrimary· Month 4
Participants were asked to indicate (from a list) their favorite activity in the game. The data presented here indicates the total number of participants in the experimental group that selected each activity as their favorite.
Investigate a guy
Group
Value
95% CI
InvestiDate Intervention
21
Trivia
Group
Value
95% CI
InvestiDate Intervention
11
Presentation
Group
Value
95% CI
InvestiDate Intervention
3
Chat with a guy
Group
Value
95% CI
InvestiDate Intervention
3
Chat with a doctor
Group
Value
95% CI
InvestiDate Intervention
0
Chat with a friend
Group
Value
95% CI
InvestiDate Intervention
0
Videos with advice from Chelsea and Brandon
Group
Value
95% CI
InvestiDate Intervention
1
Total Time PlayingPrimary· Month 4
The mean total time spent playing the videogame
Group
Value
95% CI
InvestiDate Intervention
105.56
± 12.92
Change From Baseline at 4 Months: HIV/STI Testing- SelfPrimary· Baseline, 1 month and 4 months
HIV/STI Testing- self will be used to determine if individuals who play InvestiDate will report more HIV/STI testing and partner testing in comparison to the control condition. Investigators will conduct a longitudinal analysis using a hierarchical linear mixed models approach to compare participants in the intervention group to participants in the control group on reported participant and partner HIV/STI testing from baseline across all follow-up assessments. Data presented here shows the number of participants who said YES they had been tested out of the total number of participants in each
Baseline
Group
Value
95% CI
InvestiDate Intervention
4
Non-Health Related Game
8
1 month
Group
Value
95% CI
InvestiDate Intervention
2
Non-Health Related Game
9
4 months
Group
Value
95% CI
InvestiDate Intervention
4
Non-Health Related Game
8
Change From Baseline at 4 Months: HIV/STI Testing- PartnerPrimary· Baseline, 1 month and 4 months
HIV/STI Testing- partner will be used to test the hypothesis that individuals who play InvestiDate will report more HIV/STI testing and partner testing in comparison to the control condition. The investigators will conduct a longitudinal analysis using a hierarchical linear mixed models approach to compare participants in the intervention group to participants in the control group on reported participant and partner HIV/STI testing from baseline across all follow-up assessments.
Baseline
Group
Value
95% CI
InvestiDate Intervention
8
Non-Health Related Game
10
1 month
Group
Value
95% CI
InvestiDate Intervention
8
Non-Health Related Game
11
4 months
Group
Value
95% CI
InvestiDate Intervention
4
Non-Health Related Game
8
Change in Use of CondomsSecondary· Baseline, 1 month and 4 months
At each time point, participants responded to the item "Did you use a condom the last time you had sex?" Response options were "yes", "no", and "I have never had sex". Data presented here shows the number of participants who answered YES out of the number of people in each group that responded to the question.
Baseline
Group
Value
95% CI
InvestiDate Intervention
11
Non-Health Related Game
9
1 month
Group
Value
95% CI
InvestiDate Intervention
7
Non-Health Related Game
8
4 months
Group
Value
95% CI
InvestiDate Intervention
4
Non-Health Related Game
7
Change in Self-Efficacy to Use Condoms (SECU) Using the Condom Use Self-Efficacy Scale (CUSES)Secondary· Baseline, 1 month, 4 months
The CUSES is a 28 item self-report questionnaire which elicits responses using a five-point Likert scale format, ranging from 'strongly disagree' to 'strongly agree'. 10 of the 28 items were administered and scores were summed for each item for each participant. Each of the responses is scored as follows: 'strongly disagree' = 0, 'disagree' = 1, 'undecided' = 2, 'agree' = 3 and 'strongly agree' = 4. The possible range of scores is 0-40, with higher scores indicating greater self-efficacy.
Baseline
Group
Value
95% CI
InvestiDate Intervention
24.5
± 6.35
Non-Health Related Game
27.52
± 5.7
1 month
Group
Value
95% CI
InvestiDate Intervention
29.3
± 5.46
Non-Health Related Game
26.61
± 5.56
4 months
Group
Value
95% CI
InvestiDate Intervention
28.3
± 6.07
Non-Health Related Game
28.09
± 6.64
Change in SECU Using Sexual Risk Behavior Beliefs and Self-efficacy (SRBBS)Secondary· Baseline, 1 month, 4 months
The SRBBS measure includes 3 items (e.g., "How sure ate you that you could use a condom correctly or explain to your partner how to use a condom correctly?") measured on a scale from 1 (not sure at all) to 5 (extremely sure). For each participant a mean of the 3 items was calculated. Scores range from 1-5 with higher scores indicating higher levels of self-efficacy.
Baseline
Group
Value
95% CI
InvestiDate Intervention
2.87
± 0.99
Non-Health Related Game
3.02
± 1.07
1 month
Group
Value
95% CI
InvestiDate Intervention
3.71
± 1.13
Non-Health Related Game
3.33
± 1.09
4 months
Group
Value
95% CI
InvestiDate Intervention
3.62
± 1.06
Non-Health Related Game
3.57
± 0.74
Change in Self-efficacy in Refusing Sex (SER) Using the SER Subscale of the SRBBSSecondary· Baseline, 1 month and 4 months
This subscale includes three items (e.g., "Imagine that you met someone at a party. He or she wants to have sex with you. Even though you are very attracted to each other, you're not ready to have sex. How sure are you that you could keep from having sex") rated on a scale ranging from 1 (not sure at all) to 5 (extremely sure). A mean score for the three items was calculated for each participant with score ranging from 1-5. Higher scores indicating higher levels of self-efficacy for refusing sex.
Baseline
Group
Value
95% CI
InvestiDate Intervention
4.03
± 0.81
Non-Health Related Game
3.98
± 0.87
1 month
Group
Value
95% CI
InvestiDate Intervention
4.4
± 0.75
Non-Health Related Game
3.88
± 0.94
4 months
Group
Value
95% CI
InvestiDate Intervention
4.4
± 0.83
Non-Health Related Game
4.07
± 0.88
Change in Self-efficacy in Communication Using the Self-efficacy for Communication (SECM) Subscale of the SRBBSSecondary· Baseline, 1 month and 4 months
Self-efficacy for communication was assessed using the SECM subscale of the SRBBS. This subscale includes three items (e.g., "Imagine that you and your partner have been having sex but have not used condoms. You really want to start using condoms. How sure are you that you could tell that person that you want to use condoms") rated on a scale ranging from 1 (not sure at all) to 5 (extremely sure). A mean score for the three items was calculated for each participant with score ranging from 1-5. Higher scores indicating higher levels of communication.
Baseline
Group
Value
95% CI
InvestiDate Intervention
4.14
± 0.67
Non-Health Related Game
4.13
± 0.77
1 month
Group
Value
95% CI
InvestiDate Intervention
4.45
± 0.62
Non-Health Related Game
4.06
± 0.87
4 months
Group
Value
95% CI
InvestiDate Intervention
4.37
± 0.74
Non-Health Related Game
4.05
± 0.87
Change in Self-efficacy for PrEPSecondary· Baseline, 1 month and 4 months
Self-Efficacy for using PrEP was assessed with a 4 item survey. Each item was measured on a scale ranging from 1 (strongly disagree) to 5 (strongly agree). A mean score for the three items was calculated for each participant with score ranging from 1-5. Higher scores indicating higher levels of self-efficacy.
Baseline
Group
Value
95% CI
InvestiDate Intervention
4.16
± 0.78
Non-Health Related Game
4.13
± 0.75
1 month
Group
Value
95% CI
InvestiDate Intervention
4.51
± 0.57
Non-Health Related Game
4.16
± 0.71
4 months
Group
Value
95% CI
InvestiDate Intervention
4.42
± 0.82
Non-Health Related Game
4.32
± 0.69
Sponsor's own description
The purpose of this study is to develop and evaluate an innovative behavioral HIV prevention videogame intervention to bolster motivation and provide skill-building opportunities to improve Black adolescent girls' ability to negotiate around risk including advocating for partner HIV/sexually transmitted infection (STI) testing, increasing their knowledge and awareness of HIV/STIs, and for reducing sexual risk-taking behaviors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor
· Phase 2
· recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV
· Phase 2
· recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV
· NA
· recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i
· Phase 1
· recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
· Phase 1
· recruiting
Other Yale University trials
Trials by the same sponsor.
NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking
· Phase 2
· not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing
· NA
· not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S
· NA
· not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa
· Phase 1, PHASE2
· not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 8 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04108988.